Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
September 8, 2015 4:01 PM EDT
FX006 provides substantial and persistent pain relief compared to placebo; well-tolerated with safety profile comparable to placebo
Conference call scheduled for tomorrow, September 9, 2015, at 9:00 a.m. ET
BURLINGTON, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided)... More
September 8, 2015 4:01 PM EDT
FX006 provides substantial and persistent pain relief compared to placebo; well-tolerated with safety profile comparable to placebo
Conference call scheduled for tomorrow, September 9, 2015, at 9:00 a.m. ET
BURLINGTON, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided)... More
